The MALT1 Locus and Peanut Avoidance in the Risk for Peanut Allergy

The LEAP study was a randomized controlled clinical trial in children at increased risk for peanut allergy, in which intervention using dietary introduction of peanut protein beginning in the first 4 to 11 months of life, continued until age 5 years, significantly decreased the frequency of peanut allergy later in childhood and modulated the immune response to peanuts.

All subject phenotype data will be hosted on ITN Trial Share under the LEAP study.

• Type: Cohort
• Archiver: The database of Genotypes and Phenotypes (dbGaP)